TY - JOUR T1 - Rate of FEV<sub>1</sub> decline by FEV<sub>1</sub> percent predicted in UPLIFT® and TIOSPIR® JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2016.PA307 VL - 48 IS - suppl 60 SP - PA307 AU - Michael B. Drummond AU - Donald P. Tashkin AU - Antonio Anzueto AU - Christoph Hallmann AU - Achim Mueller AU - Norbert Metzdorf AU - Ulrika Hinkel AU - Robert A. Wise Y1 - 2016/09/01 UR - http://erj.ersjournals.com/content/48/suppl_60/PA307.abstract N2 - Introduction: Studies suggest that in patients with chronic obstructive pulmonary disease, the rate of decline in FEV1 accelerates with increasing age. Factors influencing the rate of decline are poorly understood.Aims and objectives: To evaluate the relationship between mean annual rate of FEV1 decline and baseline FEV1 % predicted in patients from the Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT®) and TIOtropium Safety and Performance In Respimat® (TIOSPIR®) trials.Methods: Annual rate of trough FEV1 decline was calculated for patients on treatment &gt;2 years, stratified by disease severity (baseline FEV1 % predicted). Treatment arms were pooled.Results: Overall, decline was calculated for 4295 patients from UPLIFT® receiving either tiotropium or placebo. Demographics did not differ by baseline severity, although GOLD Stage 4 patients (baseline FEV1 % predicted &lt;30) were slightly younger (60.8 years) with a lower body mass index (BMI) (24.1) compared with other groups (63.6-64.6 years; BMI 25.9-26.8). Mean annual rate of trough FEV1 decline was greater in patients with higher baseline FEV1 % predicted and less in patients with more severe disease (Figure). A similar pattern was observed in patients from TIOSPIR®.Conclusions: In UPLIFT® and TIOSPIR®, the annual rate of decline in FEV1 is almost linearly correlated to the initial disease status (baseline FEV1 % predicted) and probably less dependent on age. ER -